- Language: English
- Published: August 2011
- Region: Global
Bulletin: Bard (C.R.) Inc. Ratings Unchanged After Company Increases Its Commercial Paper Program Jan 12
- Published: January 2012
- Standard & Poors
BOSTON (Standard & Poor's) Jan. 6, 2012-Standard & Poor's Ratings Services said today that its ratings on Murray Hill, N.J.-based medical device manufacturer C.R. Bard Inc. remain unchanged after the company recently increased the size of its commercial paper (CP) program to $600 million to match the size of its unrated credit agreement, which was executed on Oct. 12, 2011. The $200 million increase in Bard's CP program to $600 million slightly improves the company's liquidity, but it is not sufficient enough to alter our ratings or "strong" liquidity descriptor on Bard. Our 'A-1' short-term rating on Bard's CP remains unchanged. Our rating outlook on the company remains stable, reflecting our expectation that Bard will continue to expand its product...
Companies mentioned in this report are: Bard (C.R.) Inc.
Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.
Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.
SHOW LESS READ MORE >
Bard (C.R.) Inc.